• Je něco špatně v tomto záznamu ?

Exploiting the unique features of Zika and Dengue proteases for inhibitor design

T. Majerová, P. Novotný, E. Krýsová, J. Konvalinka,

. 2019 ; 166 (-) : 132-141. [pub] 20190509

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044837

Zika and Dengue viruses have attracted substantial attention from researchers in light of recent outbreaks of Dengue fever and increases in cases of congenital microcephaly in areas with Zika incidence. This review summarizes the current state of knowledge about Zika and Dengue proteases. These enzymes have several interesting features: 1) NS3 serine protease requires the activating co-factor NS2B, which is anchored in the membrane of the endoplasmic reticulum; 2) NS2B displays extensive conformational dynamics; 3) NS3 is a multidomain protein with proteolytic, NTPase, RNA 5' triphosphatase and helicase activity and has many protein-protein interaction partners; 4) NS3 is autoproteolytically released from its precursor. Attempts to design tight-binding and specific active-site inhibitors are complicated by the facts that the substrate pocket of the NS2B-NS3 protease is flat and the active-site ligands are charged. The ionic character of potential active-site inhibitors negatively influences their cell permeability. Possibilities to block cis-autoprocessing of the protease precursor have recently been considered. Additionally, potential allosteric sites on NS2B-NS3 proteases have been identified and allosteric compounds have been designed to impair substrate binding and/or block the NS2B-NS3 interaction. Such compounds could be specific to viral proteases, without off-target effects on host serine proteases, and could have favorable pharmacokinetic profiles. This review discusses various groups of inhibitors of these proteases according to their mechanisms of action and chemical structures.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044837
003      
CZ-PrNML
005      
20200113084653.0
007      
ta
008      
200109s2019 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biochi.2019.05.004 $2 doi
035    __
$a (PubMed)31077760
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Majerová, Taťána $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague 6, Czech Republic.
245    10
$a Exploiting the unique features of Zika and Dengue proteases for inhibitor design / $c T. Majerová, P. Novotný, E. Krýsová, J. Konvalinka,
520    9_
$a Zika and Dengue viruses have attracted substantial attention from researchers in light of recent outbreaks of Dengue fever and increases in cases of congenital microcephaly in areas with Zika incidence. This review summarizes the current state of knowledge about Zika and Dengue proteases. These enzymes have several interesting features: 1) NS3 serine protease requires the activating co-factor NS2B, which is anchored in the membrane of the endoplasmic reticulum; 2) NS2B displays extensive conformational dynamics; 3) NS3 is a multidomain protein with proteolytic, NTPase, RNA 5' triphosphatase and helicase activity and has many protein-protein interaction partners; 4) NS3 is autoproteolytically released from its precursor. Attempts to design tight-binding and specific active-site inhibitors are complicated by the facts that the substrate pocket of the NS2B-NS3 protease is flat and the active-site ligands are charged. The ionic character of potential active-site inhibitors negatively influences their cell permeability. Possibilities to block cis-autoprocessing of the protease precursor have recently been considered. Additionally, potential allosteric sites on NS2B-NS3 proteases have been identified and allosteric compounds have been designed to impair substrate binding and/or block the NS2B-NS3 interaction. Such compounds could be specific to viral proteases, without off-target effects on host serine proteases, and could have favorable pharmacokinetic profiles. This review discusses various groups of inhibitors of these proteases according to their mechanisms of action and chemical structures.
650    _2
$a alosterické místo $7 D000495
650    _2
$a antivirové látky $x chemie $x farmakologie $7 D000998
650    _2
$a katalytická doména $7 D020134
650    _2
$a dengue $x farmakoterapie $x virologie $7 D003715
650    _2
$a virus dengue $x účinky léků $x enzymologie $7 D003716
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a inhibitory proteas $x chemie $x farmakologie $7 D011480
650    _2
$a konformace proteinů $7 D011487
650    _2
$a serinové endopeptidasy $x chemie $x metabolismus $7 D012697
650    _2
$a virus zika $x účinky léků $x enzymologie $7 D000071244
650    _2
$a infekce virem zika $x farmakoterapie $x virologie $7 D000071243
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Novotný, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague 6, Czech Republic; Department of Biochemistry, Faculty of Science, Charles University in Prague, 12843, Prague, Czech Republic.
700    1_
$a Krýsová, Eliška $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague 6, Czech Republic; Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, 12843, Prague, Czech Republic.
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, 16610, Prague 6, Czech Republic; Department of Biochemistry, Faculty of Science, Charles University in Prague, 12843, Prague, Czech Republic. Electronic address: jan.konvalinka@uochb.cas.cz.
773    0_
$w MED00009325 $t Biochimie $x 1638-6183 $g Roč. 166, č. - (2019), s. 132-141
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31077760 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113085025 $b ABA008
999    __
$a ok $b bmc $g 1483106 $s 1083510
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 166 $c - $d 132-141 $e 20190509 $i 1638-6183 $m Biochimie $n Biochimie $x MED00009325
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...